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Abstract: Barrett’s esophagus (BE) is a premalignant condition caused by gastroesophageal reflux
disease (GERD), where physiological squamous epithelium is replaced by columnar epithelium.
Several in vivo and in vitro BE models were developed with questionable translational relevance
when implemented separately. Therefore, we aimed to screen Gene Expression Omnibus 2R (GEO2R)
databases to establish whether clinical BE molecular profile was comparable with animal and
optimized human esophageal squamous cell lines-based in vitro models. The GEO2R tool and
selected databases were used to establish human BE molecular profile. BE-specific mRNAs in
human esophageal cell lines (Het-1A and EPC2) were determined after one, three and/or six-day
treatment with acidified medium (pH 5.0) and/or 50 and 100 µM bile mixture (BM). Wistar rats
underwent microsurgical procedures to generate esophagogastroduodenal anastomosis (EGDA)
leading to BE. BE-specific genes (keratin (KRT)1, KRT4, KRT5, KRT6A, KRT13, KRT14, KRT15, KRT16,
KRT23, KRT24, KRT7, KRT8, KRT18, KRT20, trefoil factor (TFF)1, TFF2, TFF3, villin (VIL)1, mucin
(MUC)2, MUC3A/B, MUC5B, MUC6 and MUC13) mRNA expression was assessed by real-time
PCR. Pro/anti-inflammatory factors (interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13,
tumor necrosis factor α, interferon γ, granulocyte-macrophage colony-stimulating factor) serum
concentration was assessed by a Luminex assay. Expression profile in vivo reflected about 45% of
clinical BE with accompanied inflammatory response. Six-day treatment with 100 µM BM (pH 5.0)
altered gene expression in vitro reflecting in 73% human BE profile and making this the most reliable
in vitro tool taking into account two tested cell lines. Our optimized and established combined
in vitro and in vivo BE models can improve further physiological and pharmacological studies testing
pathomechanisms and novel therapeutic targets of this disorder.
Keywords: Barrett’s esophagus; esophageal epithelium; molecular profile; molecular gastrointestinal
pharmacology; molecular gastrointestinal pathophysiology
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1. Introduction
Barrett’s esophagus (BE) is a complex, genetically predisposed, premalignant condition of the distal
esophagus characterized as replacement of the esophageal squamous epithelium into an intestinal-type
columnar epithelium with a crypt-like architecture [1–3]. Epithelium in BE is usually composed of
mucous-producing cells, which aids in the protection of the esophagus from the constant insult of acid
and bile [2]. BE affects 2% of the adult population in the Western world [4,5]. It has been confirmed that
chronic gastroesophageal reflux disease (GERD) is one of the most important etiological component of
BE [4,5].
Importantly, BE and GERD are closely associated with a high risk of developing esophageal
adenocarcinoma (EAC). EAC has a very poor prognosis with a 9–15% five-year survival rate [4].
The pattern of reflux is a significant factor that may influence the progression of BE towards
advanced precancerous changes [6,7]. In contrast to the physiological esophageal epithelium, the BE
development results in alternation of several individual molecular markers and signaling pathways.
These changes include variety of mucins (MUC), mucin-associated trefoil factor family (TFF) peptides,
and villin (VIL) [8–10]. However, the physiological and pathophysiological aspects still require
further investigation, especially in the context of the implementation of novel non-invasive methods of
treatment of this disorder.
Both BE and GERD are related to inflammation of the esophageal epithelium. Chronic inflammation
in BE has been linked to DNA damage, leading to mutations and genomic instability, and altered
expression of genes that are involved in cellular proliferation and programmed cell death [11].
The inflammatory response also includes increased oxidative stress, activation of several signaling
pathways, and the release of inflammatory cytokines [11]. Moreover, chronic inflammation can lead to
a higher rate of cellular turnover, which is typical for BE and can alter the pattern of gene expression in
epithelial cells [11]. For example, an analysis of keratin (KRT), a major constituent of the esophageal
epithelium, revealed significant changes from those keratins normally expressed in squamous epithelia
to those expressed in columnar epithelium [8,12,13].
The diagnostic criteria for BE phenotype requires endoscopic identification of columnar mucosa
and microscopic appearance of columnar epithelium with presence of goblet cells within the
esophageal mucosa [3]. The basic therapeutic options for patients with BE include pharmacological
treatment with proton pump inhibitors or endoscopic procedures with surgical resection, and
chemo- and radiotherapy [14]. However, the evidence from randomized controlled trials shows
that pharmacological and surgical therapies do not completely prevent or eliminate BE and existing
dysplasia [14]. Therefore, the development of novel or alternative pharmacological therapeutic
interventions seems to be justified, also taking into account the recently published evidence [5]. Current
advances in the understanding of the complex molecular mechanisms of BE development, which
came from experimental models of BE, include overexpression of cyclooxygenase-2 (COX-2) [15,16],
epidermal growth factor (EGF) [17–19], or mitogen-activated protein kinase (MAPK) and the protein
kinase phosphorylation (PI3K) pathways [20,21], as well as increased secretion of gastrin due to
achlorhydria as a complication of prolonged proton pomp inhibitors (PPI) therapy [22]. However,
many ongoing controversies and challenges and potential mediators responsible for the development
of BE still remain unsolved. Additionally, the conversion process of normal squamous epithelium
towards Barrett’s metaplasia is difficult to monitor directly under clinical conditions [23]. Thus, over the
last few years, several experimental models using various types of cell cultures and animal models have
been published to investigate the mechanisms of bile and/or acid exposure in BE pathogenesis [1,23].
However, the relevance of each of the models implemented separately is considered to be questionable.
Therefore, this study was designed to establish relevant experimental models for further studies
emphasizing the effectiveness of possible protective treatment of BE esophageal metaplasia with
pharmacological agents. Thus, we selected appropriate translational molecular markers such as KRT,
MUC, TFF and VIL genes to compare expression profiles in clinical biopsies derived from BE patients
with the animal surgical model and an in vitro model of BE involving two human-derived primary
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immortalized esophageal cell lines. We put special emphasis on the optimization of this in vitro model
with the aim to reflect the molecular events observed clinically as closely as possible.
2. Results
2.1. Analysis of BE Expression Profile for Selected Genes in Human Biopsies Based on GSE Datasets
Expression of mRNA for squamous epithelium-specific genes such as KRT1, KRT4, KRT5, KRT6A-C,
KRT13, KRT14, KRT15, KRT16, KRT23, KRT24 was significantly decreased in human Barrett’s esophagus
biopsies as compared with expression of these specific genes in samples collected from normal
squamous epithelium and observed in at least one out of three analyzed databases (p < 0.05, Table 1).
Expression of mRNA for columnar and intestinal epithelium-specific genes such as KRT7, KRT8,
KRT18, KRT20, TFF1, TFF2, TFF3, VIL1, MUC2, MUC3A/B, MUC5B, MUC6, MUC13 was significantly
upregulated in human BE biopsies when compared with gene expression in samples collected from
normal squamous epithelium in at least one out of three analyzed databases (p < 0.05, Table 1).
Genes such as KRT10, KRT17, KRT19, MUC1, MUC5ac, MUC12, MUC15, MUC17 and MUC21 did not
fulfil our selection criteria and were not interpreted (Table 1).
2.2. The Effect of Exposition to Various Bile Mixture (BM) Concentrations and pH Values on the Viability of
Esophageal Epithelial Cell Lines
To determine the effect of the exposure to BM on cell viability, cells were incubated for 30 min with
various BM concentrations (0–800 µM) in regular or low pH (pH 5.0) cell culture medium (Figure 1A,B).
Figure 1A,B show no significant changes in cell viability when BM (0–800 µM) was applied in regular
medium in both cell lines as compared with control cells not exposed to BM. In contrast, when Het-1A
and EPC2 cells were incubated with BM in the concentrations≥200µM and at low pH, a dose-dependent
and significant decrease in cell viability was observed in comparison to the respective doses of BM
applied in regular medium (p < 0.05, Figure 1A,B).
Figure 1. The effect of exposure to various concentrations of bile mixture (BM) and different pH on
the viability of esophageal epithelial cell lines. Het-1A (A) and EPC2 (B) cells were treated for 30 min
with BM at concentrations ranging from 0 to 800 µM. After 24 h, MTT assay was used to determine cell
viability. Significant changes (p < 0.05) in cell viability after BM treatment at pH 5.0 as compared to the
treatment with BM in regular medium were indicated by asterisk (*).
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Table 1. Alterations in selected genes expression in human biopsies derived from patients with Barrett’s metaplasia as compared with normal squamous epithelium,
based on analysis of the database no GSE13083 [8], GSE34619 [9] and GSE1420 [24]. Asterisk (*) indicates statistically significant difference with p < 0.05 in parallel
with logFC values lower than −2 or higher than 2.
Database No GSE13083 (n = 7): Barrett’s
Metaplasia (7 Samples) vs. Normal
Squamous Epithelium (7 Samples)
Database No GSE34619 (n = 18): Barrett’s
Metaplasia (n =10) vs. Normal Squamous
Epithelium (n = 8)
Database No GSE1420 (n = 16): Barrett’s
Metaplasia (n = 8) vs. Normal Squamous
Epithelium (n = 8)
Gene Symbol Predicted Type ofEpithelium Gene ID logFC p Value Gene ID logFC p Value Gene ID logFC p Value
KRT1 squamous (esophageal) 205900_at −7.49126 1.11e−05 * 7963491 −3.3024845 1.10e−03 * 205900_at −2.217323 0.277797
KRT4 squamous (esophageal) 213240_s_at −4.6401743 5.80e−02 7963534 −5.428193 2.16e−05 * 214399_s_at 0.9627934 0.291337
KRT5 squamous (esophageal) 201820_at −6.9473657 1.02e−02 * 7963427 −5.19733 1.27e−05 * 201820_at 0.2659335 0.939807
KRT6A, 6B, 6C squamous (esophageal) 214580_x_at −5.0172743 3.66e−02 * 7963410 −4.5273685 7.31e−05 * 214580_x_at 0.3930203 0.885997
KRT10 squamous (esophageal) 207023_x_at −1.9265443 4.80e−03 * 8015104 −1.9039765 1.43e−02 * 207023_x_at 0.0731168 0.925068
KRT13 squamous (esophageal) 207935_s_at −5.3344986 4.04e−02 * 8015323 −5.5419725 5.55e−05 * 207935_s_at 0.4701058 0.861817
KRT14 squamous (esophageal) 209351_at −4.0982471 1.17e−01 8015366 −2.2296553 1.88e−03 * 209351_at 1.928972 0.499067
KRT15 squamous (esophageal) 204734_at −6.05938 2.09e−03 * 8015337 −4.686177 2.79e−10 * 204734_at −0.327417 0.941066
KRT16 squamous (esophageal) 209800_at −5.0731586 5.63e−03 * 8015376 −3.5205307 2.61e−05 * 209800_at 1.16582 0.682918
KRT17 squamous (esophageal) 212236_x_at −2.6745814 8.21e−02 8005449 −1.7824035 1.42e−03 * 205157_s_at 2.6061311 0.297826
KRT23 squamous (esophageal) 218963_s_at −2.0889186 3.74e−02 * 8015133 −1.2800192 7.70e−02 218963_s_at 0.0060589 0.997257
KRT24 squamous (esophageal) 220267_at −4.4806771 2.26e−03 * 8015060 −2.905637 7.73e−05 * 220267_at −0.676433 0.81305
KRT7 columnar (intestinal) 209016_s_at 2.2155471 4.07e−02 * 7955613 1.9065172 5.46e−06 * 209016_s_at 1.6998427 0.204673
KRT8 columnar (intestinal) 209008_x_at 6.4172871 2.18e−09 * 7963567 4.0091988 3.50e−11 * 209008_x_at 2.6806701 0.027973 *
KRT18 columnar (intestinal) 201596_x_at 3.4490243 5.03e−06 * 8154725 2.024285 2.16e−06 * 201596_x_at 1.9282774 0.082523
KRT19 columnar (intestinal) 201650_at 1.7536714 1.01e−03 * 8015349 0.759105 3.08e−02 201650_at 1.2141959 0.658343
KRT20 columnar (intestinal) 213953_at 8.5259443 3.44e−09 * 8015124 4.374532 2.00e−04 * 213953_at 4.8072071 0.037302 *
TFF1 columnar (intestinal) 205009_at 8.2017486 1.75e−05 * 8070579 6.4595337 1.46e−12 * 205009_at 5.6843253 0.010407 *
TFF2 columnar (intestinal) 214476_at 7.6665729 4.86e−05 * 8070574 5.2354248 1.23e−08 * 214476_at 5.8714482 0.006909 *
TFF3 columnar (intestinal) 204623_at 8.9897857 9.11e−08 * 8070567 2.2346355 2.20e−04 * 204623_at 3.3738183 0.110978
VIL1 columnar (intestinal) 209950_s_at 5.8340643 8.63e−09 * 8078665 2.2711873 1.88e−08 * 209950_s_at 2.5215122 0.025483 *
MUC1 columnar (intestinal) 213693_s_at 1.5493643 1.21e−01 7920642 1.9449625 1.69e−05 * 213693_s_at 1.1435938 0.427828
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Table 1. Cont.
Database No GSE13083 (n = 7): Barrett’s
Metaplasia (7 Samples) vs. Normal
Squamous Epithelium (7 Samples)
Database No GSE34619 (n = 18): Barrett’s
Metaplasia (n =10) vs. Normal Squamous
Epithelium (n = 8)
Database No GSE1420 (n = 16): Barrett’s
Metaplasia (n = 8) vs. Normal Squamous
Epithelium (n = 8)
Gene Symbol Predicted Type ofEpithelium Gene ID logFC p Value Gene ID logFC p Value Gene ID logFC p Value
MUC2 columnar (intestinal) 204673_at 6.7226214 3.16e−06 * 7937560 2.1981597 2.77e−03 * 204673_at 2.9508572 0.271622
MUC3A/B columnar (intestinal) 217117_x_at 0.7757457 9.80e−02 8135015 4.3127432 6.68e−09 * 217117_x_at 0.9212935 0.225325
MUC4 columnar (intestinal) 217109_at −1.07354 1.13e−01 8092978 0.1271057 8.92e−01 204895_x_at 1.903752 0.360547
MUC5ac columnar (intestinal) 214385_s_at 8.1766871 8.25e−07 * not included in the database 214385_s_at 7.1466461 0.005318 *
MUC5B columnar (intestinal) 213432_at 2.7593857 4.75e−02 * 7937612 1.6075105 2.00e−03 * 213432_at 2.3107749 0.510519
MUC6 columnar (intestinal) 214133_at 3.1026371 7.45e−03 * 7945595 5.9384813 1.46e−11 * 214133_at 3.4098322 0.017934 *
MUC12 columnar (intestinal) not included in the database 8135033 2.2172345 1.33e−03 * not included in the database
MUC13 columnar (intestinal) 218687_s_at 7.3541829 5.65e−10 * 8090180 7.3474513 1.87e−11 * 218687_s_at 3.6273263 0.031468 *
MUC15 columnar (intestinal) not included in the database 7947156 −4.7653307 4.28e−10 * not included in the database
MUC17 columnar (intestinal) not included in the database 8135048 5.953779 6.32e−08 * not included in the database
MUC21 columnar (intestinal) not included in the database 8177931 −5.732196 5.46e−07 * not included in the database
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2.3. Optimization of the Experimental Procedure Duration
To identify the optimal duration of acidic BM treatment in the establishment of an in vitro model
of BE-type molecular profile development, based on the analysis of GSE datasets, two squamous (KRT4,
KRT15) and two columnar (KRT8, KRT18) epithelium-specific genes were randomly selected. For this
purpose, Het-1A (Figure 2A–D) and EPC2 (Figure 3A–D) cell lines were daily exposed for 30 min to
acidified medium (pH 5.0) and/or 100 µM of bile mixture (BM) for one, three or six consecutive days.
The concentration of 100 µM of BM (pH 5.0) was selected based on previous experiments documenting
that this concentration was the highest concentration at which the cell viability was not significantly
affected (Figure 1A,B).
Figure 2. The effect of treatment with bile mixture (BM), acidified medium alone or acidic BM for one,
three and six consecutive days on KRT4, 15, 8 and 18 mRNA expression in Het-1A cell line. Het-1A
cell line underwent 30 min of daily incubation with BM at concentration of 100 µM, acidified medium
to pH 5.0 alone or BM (100 µM) in acidified medium (pH 5.0) for one, three or six consecutive days
and expression of KRT4, KRT15, KRT8 and KRT18 mRNA was analyzed by real-time PCR (A–D).
PCR reaction was performed in duplicates and quantified using ACTB/GAPDH as reference genes.
Data from three independent experiments are shown as the mean ± SEM. An asterisk (*) indicates a
significant change as compared with untreated control cells (p < 0.05). Significant change (p < 0.05) in
gene expression as compared with one day exposure to respective treatment regime is indicated by a
hash (#). A cross (+) indicates a significant change as compared with cells after three days of treatment
for respective treatment regime (p < 0.05).
No amplification of KRT4 gene was observed in Het-1A cell line (Figure 2A) but Figure 3A shows
that at 100 µM BM in acidified medium, a significant downregulation of the expression of squamous
epithelium-specific KRT4 mRNA in EPC2 cells was observed after one, three and six days of treatment,
in comparison to untreated control cells (p < 0.05). Moreover, KRT4 mRNA level in EPC2 cells was
significantly decreased after six days in comparison to one and three days of treatment (p < 0.05;
Figure 3A). Additionally, the low pH and 100 µM BM applied separately to EPC2 cells for six but not
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three days significantly inhibited KRT4 mRNA expression in comparison to untreated control cells and
to respective experimental group after one day of treatment (p < 0.05; Figure 3A).
Figure 3. The effect of treatment with bile mixture (BM), acidified medium alone or acidic BM for one,
three and six consecutive days on KRT4, 15, 8 and 18 mRNA expression in EPC2 cell line. EPC2 cell
line underwent 30 min of daily incubation with BM at concentration of 100 µM, acidified medium
to pH 5.0 alone or BM (100 µM) in acidified medium (pH 5.0) for one, three or six consecutive days
and expression of KRT4, KRT15, KRT 8 and KRT18 mRNA was analyzed by real-time PCR (A–D).
PCR reaction was performed in duplicates and quantified using ACTB/GAPDH as reference genes.
Data from three independent experiments are shown as the mean ± SEM. An asterisk (*) indicates a
significant change as compared with untreated control cells (p < 0.05). Significant change (p < 0.05) in
gene expression as compared with one day exposure for respective treatment regime is indicated by
hash (#). A cross (+) indicates a significant change as compared with cells after three days of treatment
(p < 0.05).
Figures 2B and 3B show significant downregulation of KRT15 mRNA expression in both cell lines
after six days as compared to untreated control cells and to one and three days of treatment with BM at
pH 5.0 (p < 0.05). Additionally, in Het-1A cells low pH alone decreased levels of KRT15 mRNA after
six days in comparison to untreated control cells and to cells after one and three days of treatment
(p < 0.05; Figure 2B). Moreover, we have noticed that 100 µM BM applied at regular medium to Het-1A
cells for six days significantly downregulated KRT15 mRNA expression in comparison to untreated
control cells and to cells after one day of treatment (p < 0.05; Figure 2B). In EPC2 cells low pH alone
inhibited KRT15 mRNA expression after 6 days, in comparison to untreated control cells and to cells
after one day of treatment (p < 0.05; Figure 3B). BM applied in concentration 100 µM (regular pH 7.2)
for six days significantly decreased KRT15 mRNA level in EPC2 cells in comparison to respective
untreated control cells (p < 0.05; Figure 3B).
Our time sequence determination revealed that a significant upregulation of KRT8 mRNA was
observed exclusively in Het-1A but not in EPC2 cells after six days as compared with one and three
days of treatments or with untreated control cells (p < 0.05; Figures 2C and 3C). KRT18 mRNA was
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significantly upregulated in EPC2 but not in Het-1A cell line after three and six days as compared with
one day of treatment or with untreated control cells (p < 0.05; Figures 2D and 3D).
To summarize, two out of three and three out of four genes from the BE molecular profile, Het-1A
and EPC2, respectively, show a significantly higher fold change after six days of acidic BM treatment,
compared to one or three days of treatment. As the fold change in expression between BE and squamous
epithelium is most resembled by the model using six days of acidic BM treatment, this condition was
selected for further study.
2.4. Squamous and Columnar Epithelium-Specific Genes Expression in In Vitro Model
Figure 4A–J show changes in mRNA expression for squamous epithelium-specific genes, selected
based on Table 1 analysis, as characteristic for human BE biopsies, determined in Het-1A and EPC2
cells treated for 30 min per day with 0 µM, 50 µM, and 100 µM BM at either pH7.2/3 or pH 5.0, for
six consecutive days. Incubation of EPC2 cells with 100 µM BM at pH 5.0 resulted in a significant
decrease in expression of all investigated squamous epithelium-specific KRT (KRT1, KRT4, KRT5,
KRT6, KRT13, KRT14, KRT15, KRT16, KRT23, KRT24) genes as compared to untreated control cells
(p < 0.05; Figure 4A–J). Significant downregulation of KRT1 (4A), KRT4 (4B), KRT5 (4C), KRT6 (4D),
KRT14 (4F), KRT16 (4H) and KRT24 (4J) mRNA as compared to EPC2 cells incubated with low pH
alone was observed (p < 0.05). Incubation of EPC2 cells with lower concentration of BM (50 µM) at pH
5.0 significantly downregulated mRNA expression of KRT1 (4A), KRT4 (4B), KRT6 (4D), KRT13 (4E),
KRT15 (4G) KRT23 (4I) and KRT24 (4J) in comparison to untreated control cells (p < 0.05). Exposure of
EPC2 cells to 100 µM of BM at regular medium resulted in a significant decrease in KRT1 (4A), KRT4
(4B), KRT15 (4G) and KRT23 (4I) mRNA levels as compared to untreated control cells (p < 0.05). In turn,
50 µM of BM applied alone inhibited mRNA expression of KRT1 (4A) and KRT4 (4B) in comparison
to untreated control EPC2 cells (p < 0.05). The mRNA expression of KRT1 (4A), KRT4 (4B), KRT13
(4E), KRT15 (4G) and KRT23 (4I) in EPC2 cells cultured in acidified medium (pH 5.0) without BM was
significantly inhibited as compared to untreated control cells (p < 0.05). In Het-1A cells, no mRNA
amplification of KRT1 (4A), KRT4 (4B), KRT5 (4C), KRT13 (4E), KRT14 (4F) KRT23 (4I) and KRT24 (4J)
and no changes in mRNA expression of KRT 6 (4D) and KRT16 (4H) was observed in all experimental
groups. Only KRT15 mRNA expression was significantly downregulated in Het-1A cells after the
treatment with BM (100 µM) at pH 5.0, as compared to untreated control cells (p < 0.05; Figure 4G).
Figure 5A–G show mRNA expression of columnar epithelium-specific genes, selected based on
Table 1 analysis, altered in patients with BE, and determined in Het-1A and EPC2 cells. In EPC2 cells
treated with 100 µm BM at pH 5.0, significant upregulation of KRT7 (5A), KRT18 (5C) and TFF3 (5D)
mRNA expression in comparison to untreated control cells and cells treated with low pH alone was
observed (p < 0.05). In contrast, exposure to 50 µM BM at pH 5.0 significantly elevated only TFF3 mRNA
expression in EPC2 cells (p < 0.05; Figure 5D). When BM (100 µm) at pH 5.0 was co-incubated with
Het-1A cells, the upregulation of KRT8 (5B), TFF3 (5D), MUC2 (5E), MUC13 (5F) and VIL1 (5G) mRNA
was detected as compared to untreated control cells (p < 0.05). In turn, BM applied at the concentration
of 50 µM at pH 5.0 significantly elevated only TFF3 (5D) and MUC13 (5F) mRNA expression over the
mRNA expression levels obtained in untreated control Het-1A cells (p < 0.05). Likewise, BM (100 µM)
applied at regular medium significantly increased mRNA expression of TFF3 as compared to untreated
control Het1A cells (p < 0.05; Figure 5D). In Het-1A cells cultured in acidified medium (pH 5.0) without
BM significant upregulation of KRT8 (5B), TFF3 (5D), MUC2 (5E), MUC13 (5F) and VIL1 (5G) mRNA
was determined as compared to untreated control cells (p < 0.05). No amplification was observed for
either KRT20, TFF1, TFF2, MUC6, MUC5B and MUC3A/B mRNA in all experimental groups for both
cell lines (data not shown).
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Figure 4. Squamous epithelium-specific mRNA expression upon incubation of Het-1A and EPC2
cells with bile mixture (BM) at pH 5.0. Het-1A and EPC2 cell lines were incubated with BM (50
µM and 100 µM) in acidified medium (pH 5.0) or regular medium for six consecutive days and
squamous epithelium-specific mRNA expression was analyzed by real-time PCR (A–J). PCR reaction
was performed in duplicates and quantified using ACTB/GAPDH as reference genes. Data from three
independent experiments are shown as the mean ± SEM. Significant change in gene expression after
six days of treatment as compared with untreated control cells is indicated by an asterisk (*) (p < 0.05).
A cross (+) indicates a significant change as compared with cells incubated with pH 5.0 alone (p < 0.05).
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Figure 5. Columnar epithelium-specific mRNA expression upon incubation of Het-1A and EPC2
cells with bile mixture (BM) at pH 5.0. Het-1A and EPC2 cell lines were incubated with BM
(50 µM and 100 µM) in acidified medium (pH 5.0) or regular medium for six consecutive days
and squamous epithelium-specific mRNA expression was analyzed by real-time PCR (A–G). PCR
reaction was performed in duplicates and quantified using ACTB/GAPDH as reference genes. Data
from representative three independent experiments are shown as the mean ± SEM. Significant change
in gene expression after six days of treatment as compared with untreated control cells is indicated by
an asterisk (*) (p < 0.05). A cross (+) indicates a significant change as compared with cells incubated
with pH 5.0 alone (p < 0.05).
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2.5. Morphology of Esophageal Mucosa, Gastroesophageal Junction (GEJ), and Gastric Cardia in Rats with
Esophagogastroduodenal Anastomosis (EGDA)
Table 2 shows that in rats with 10 weeks of EGDA, the lesion score assessed macroscopically
reached three in 70% of cases (7 out of 10 animals). In 20% of rats, disease progression reached score
four and only 10% of animals reached lesion score two (Table 2).
Table 2. Incidence of the particular macroscopic lesion score in esophageal mucosa of rats 10 weeks
after esophagogastroduodenal anastomosis (EGDA)-inducing surgery.
Macroscopic Lesion Score Number of Animals with EGDA (%) (n = 10)
2 1 (10%)
3 7 (70%)
4 2 (20%)
Figure 6 shows the macroscopic appearance of esophageal mucosa, GEJ, and gastric cardia of
representative rats with or without EGDA (Figure 6A,B, respectively). After exposure to chronic reflux
due to EGDA, thickening of esophageal wall with ulceration and papillomatosis of the esophageal
mucosa surface was observed (Figure 6B).
Figure 6. Macroscopic appearance of esophageal mucosa, gastroesophageal junction and gastric cardia
in representative rats without (Intact, A) or with esophagogastroduodenal anastomosis (EGDA, B).
Table 3 shows that all 10 animals with EGDA developed hyperplasia of squamous epithelium and
fibrosis of the lamina propria at 10 weeks after surgery. In 80% of the rats, esophagitis with ulceration
was observed (Table 3). Barrett’s metaplasia was present in 60% of the rats (Table 3).
Table 3. Incidence of the selected microscopic criteria in esophageal mucosa of rats 10 weeks after
esophagogastroduodenal anastomosis (EGDA)-inducing surgery.
Assessed Microscopic Criteria Number of Animals with EGDA with Presence ofthe Criteria (%) (n = 10)
hyperplasia of squamous epithelium 10 (100%)
fibrosis of lamina propria 10 (100%)
Barrett’s metaplasia 6 (60%)
esophagitis with ulceration 8 (80%)
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Figure 7A1,A2 shows the microscopic appearance of the esophageal mucosa, GEJ, and gastric
mucosa obtained from representative intact rats. The typical morphology manifestation of hyperplasia,
fibrosis or inflammation of experimental BE was not observed in esophageal epithelium and submucosa
attached to the GEJ of intact rats (Figure 7A1) and the AB/PAS staining did not show any pathological
changes within the tissue of these rats (Figure 7A2). In contrast, Figure 7B1,B2 shows that in rats with
EGDA, the GEJ architecture is altered. Esophageal mucosa is characterized by evident ulceration
and fibrosis as demonstrated in the high resolution image (Figure 7B3). Moreover, Barrett’s-like
lesions metaplasia with presence of AB-positive goblet cells is observed proximally from the GEJ
(Figure 7B3,B4). Figure 7B5,B6 presents photomicrographs of esophageal tissue section collected
separately from the same rate, as shown in Figure 7B3,B4. In animals with EGDA, the esophageal
squamous mucosa shows pronounced epithelial hyperplasia (Figure 7B5,B6).
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Figure 7. Microscopic appearance of esophageal mucosa, gastroesophageal junction (GEJ) and
gastric cardia stained with haematoxylin/eosin (H&E) or alcian blue/periodic acid-Schiff (AB/PAS)
in representative rats without (A1,A2) or with an esophagogastroduodenal anastomosis (B1–B6).
Grey arrow points out gastric mucosa, blue arrow points out GEJ, red arrow indicates esophageal mucosa,
yellow arrow indicates esophageal ulceration, orange frame shows Barrett’s-like lesions (A1,A2,B1,B2).
(B3,B4) show high resolution images of Barrett’s-like lesions where yellow arrows indicate goblet cells
and green arrows indicate fibrosis. Yellow arrows indicate epithelial hyperplasia (B5,B6).
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2.6. Alterations in Serum Content of Pro- and Anti-Inflammatory Cytokines in Rats with EGDA
Figure 8A–K shows that serum contents of interleukin (IL)-1β (10A), IL-2 (10B), IL-4 (10C),
IL-5 (10D), IL-6 (10E), IL-10 (10F), IL-12 (10G), IL-13 (10H), interferon (IFN)-γ (10I), tumor necrosis factor
(TNF)-α (10J), and granulocyte-macrophage colony-stimulating factor (GM-CSF) (10K), respectively,
were significantly increased in rats with EGDA as compared with intact animals (p < 0.05).
Figure 8. Serum concentration of interleukin (IL)-1β (A), IL-2 (B), IL-4 (C), IL-5 (D), IL-6 (E),
IL-10 (F), IL-12 (G), IL-13 (H), interferon (IFN)-γ (I), tumor necrosis factor (TNF)-α (J), and
granulocyte-macrophage colony-stimulating factor GM-CSF (K) in rats without (intact) and with
esophagogastroduodenal anastomosis (EGDA). Results are mean ± SEM of five samples per each
experimental group. Asterisk (*) indicates a significant change as compared with respective values
obtained in rats without EGDA (p < 0.05).
2.7. Squamous and Columnar Epithelium-Specific mRNA Expression in Esophageal Mucosa of Rats
with EGDA
Figure 9 shows expression of squamous epithelium-specific (A–G) genes in esophageal mucosa of
rats with EGDA. In esophageal mucosa of rats with EGDA, KRT4 (9A), KRT13 (9D) and KRT15 (9F)
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mRNA expression was significant downregulated in line with in vitro model and KRT1 (9A), KRT5
(9C) and KRT14 (9E) mRNA fold changes were significantly increased not in line with in vitro model as
compared to intact rats (p < 0.05). EGDA did not significantly affect mRNA expression of KRT23 (9G).
Figure 9. Expression of mRNA for squamous epithelium-specific genes in rats without (intact) and
with esophagogastroduodenal anastomosis (EGDA). Results are expressed as mRNA expression of
squamous epithelium-specific genes (A–G) normalized to ACTB/GAPDH expression and are mean
± SEM for n = 5 samples per each experimental group. Asterisk (*) indicates a significant change as
compared with respective values obtained in rats without EGDA (p < 0.05).
Figure 10 shows that the mRNA expression of columnar epithelium-specific genes KRT7 (10A),
KRT8 (10B), KRT18 (10C), KRT20 (10D), TFF3 (10F), MUC2 (10H) and MUC13 (10I) was significantly
upregulated in rats with EGDA in comparison to intact rats (p < 0.05). Only TFF1 (10E) mRNA was
downregulated after EGDA. EGDA did not lead to any significant changes in VIL1 (10G) mRNA
expression. No amplification was observed for KRT6, KRT16, KRT24, TFF2, MUC3A, MUC5B and
MUC6 mRNA in rats (data not shown).
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Figure 10. Expression of mRNA for columnar epithelium-specific genes in rats without (intact) and
with esophagogastroduodenal anastomosis (EGDA). The results are expressed as mRNA expression of
columnar epithelium-specific genes (A–I) normalized to ACTB/GAPDH expression and are the mean ±
SEM for n = 5 Barrett’s-like samples per experimental group. Asterisk (*) indicates a significant change
as compared with respective values obtained in rats without EGDA (p < 0.05).
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3. Discussion
Human BE is a pathological condition associated with longstanding GERD and is defined as
metaplasia of the flat, layered esophageal squamous epithelium into a tall intestinal columnar epithelial
cells [23,25]. It is important to highlight that Barrett’s metaplasia may originate from GEJ stem
cells [26,27].
In our study, we have aimed to establish an appropriate experimental model that enables the
evaluation of the effectiveness of novel pharmacological tools in the pathophysiology of Barrett’s
metaplasia development at the microscopic, systemic, and especially molecular levels. For this purpose,
we have chosen three datasets GSE13083 [8], GSE34619 [9] and GSE1420 [24] from Gene Expression
Omnibus (GEO) and applied them to the GEO2R online tool to select the commonly expressed
genes in BE epithelium. We observed significant downregulation in mRNA expression for squamous
epithelium-specific genes such as KRT1, KRT4, KRT5, KRT6A-C, KRT13, KRT14, KRT15, KRT16, KRT23
and KRT24 in human BE biopsies as compared with samples collected from normal squamous
esophageal epithelium. In turn, expression of mRNA for columnar and intestinal epithelium-specific
genes such as KRT7, KRT8, KRT18, KRT20, TFF1, TFF2, TFF3, VIL1, MUC2, MUC3A/B, MUC5B, MUC6
and MUC13 was significantly upregulated. We assume that the alterations in the mRNA expression of
the abovementioned specific genes reflect the development of metaplasia within the epithelium at the
molecular level.
There have been several attempts to develop experimental in vivo models of GERD leading to BE
and/or EAC, which attempt to mimic the clinical course of this disorder. The most widely described
model in literature is the surgical animal model with rats [28]. Attwood et al. divided existing reflux
models into three categories depending on the production of esophagitis alone (rat pyloric ligation,
Wendel esophagogastroplasty, or external esophageal perfusion), esophagitis and BE but not EAC
(total gastrectomy or mucosal excision with hiatal hernia creation), and esophagitis, BE, and EAC
(esophagojejunostomy, esophagoduodenal anastomosis, or esophagogastroduodenal anastomosis) [29].
Interestingly, Quante et al. demonstrated that genetically modified mice overexpressing IL-1β also
develop Barrett’s-like lesions [26].
We have selected and implemented the well-known surgical rat model based on generation of
an appropriate anastomosis according to the method described previously by Nishijima et al. [30].
Microscopic and histological analysis confirmed BE metaplasia with the presence of goblet cells in 60%
of rats with 10 weeks of EGDA.
Additionally, we have demonstrated an evident increase in the expression of pro/anti-inflammatory
cytokines in rats with experimental gastroduodenoesophageal reflux. This is corroborative with
previous findings that find that chronic inflammation of esophageal mucosa may occur as the
secondary consequence of multiple exposures of esophageal structure to the acidic and alkaline content.
Thus, there is no doubt that this gastroduodenal content may represent a common risk factor in the BE
pathogenesis and its further progression [7,15,30–32].
Moreover, based on the analysis of the BE expression profile in human biopsies, we sought to
identify alterations in mRNA expression of selected genes including squamous epithelium-specific
(KRT1, KRT4, KRT5, KRT6, KRT13, KRT14, KRT15, KRT16, KRT23, KRT24) and columnar
epithelium-specific (KRT7, KRT8, KRT18, KRT20) keratins together with secretory (MUC2, MUC5B,
MUC6) and epithelial membrane-bound (MUC3A/B) mucins, trefoil factor family (TFF1, TFF2, TFF3)
and villin (VIL1) genes in the esophageal mucosa of rats with EGDA in comparison to intact rats without
EGDA. We found that expression of squamous epithelium-specific KRT4, KRT13 and KRT15 mRNA
was significantly downregulated in esophageal mucosa of rats with EGDA. These findings seem to
closely correlate with changes in mRNA expression as demonstrated in mucosal biopsies collected from
patients with BE. In addition, among investigated columnar epithelium-specific genes KRT7, KRT8,
KRT18, KRT20, TFF3, MUC2 and MUC13 mRNA expression was significantly upregulated reflecting
changes observed in BE patients. In contrary, KRT1, KRT5, KRT14, TFF1 and VIL1 mRNA expression was
increased in animal biopsies, which is not in line with the expression of these genes observed in human
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BE biopsies. This phenomenon can be explained by species-specific discrepancy between humans and
rodents, especially taking into account that KRT1, KRT5 and KRT14 are expressed in human squamous
epithelium. The direct translational character of the scientific data derived from animal studies related
to BE and compared with human BE can be doubtful when considering e.g., the variability in the
structure and physiology between the rodent and human esophagus (Table 4) [33,34].
Table 4. Major differences between human and rat esophagus physiology and Barrett’s esophagus
(BE) pathophysiology.
Human Rat
Esophageal epithelium non-keratinized keratinized
Esophageal submucosal glands and papillae Present Absent
Stratum corneum Absent Present
Squamocolumnar transition at GEJ yes no
Natural reflux yes no
Natural BE to EAC progression yes no
Compartmentalized stomach (forestomach and distal stomach) no yes
BE progression time 10 years Around 2–3 months
The data accumulated in our study may support the notion proposed by Attwood et al. that
results from animal models cannot be always translated to clinical settings [27]. Thus, if the results
are achieved without the solid pathology background, experimental as well as molecular evidences,
the results of subsequent work must be interpreted carefully [29]. Therefore, there is a great need for
alternative methods that will be more available, will not depend on the presence of BE patients, and
strive to mimic the human in vivo microenvironments in an in vitro setting [35]. For instance, Bus et al.
reviewed a large variety of in vitro models and incubation conditions for studying BE development [1].
In their in vitro studies, bile salts at either a low or neutral pH were required to induce expression of
BE-specific factors [1]. Moreover, they proposed that the esophageal squamous epithelium cell lines,
such as the Het-1A cells, appear to be the most appropriate models for studying BE pathogenesis [1].
On the contrary, according to Underwood et al., Het-1A cell line does not possess the characteristics of
normal esophageal squamous cells and should be studied with caution in translator research on BE [36].
Thus, in addition to the commonly used Het-1A cell line, we have implemented human esophageal
keratinocytes EPC2 cell line to investigate their molecular response to acid and/or BM exposures.
Since the major constituent of the esophageal epithelium are the keratins [35,37], we chose them
as a focal point to investigate the molecular pattern of Barrett’s metaplasia and to identify the optimal
duration of acid and/or BM treatment to establish an in vitro model of BE development. Based on cell
viability analysis we have selected BM at the concentration of 100 µM applied in medium adjusted
to pH 5.0 as the highest concentration, which did not affect esophageal cell lines survival. We have
further assessed possible time-dependent alterations in the expression of two squamous (KRT4, KRT15)
and two columnar (KRT8, KRT18) epithelium-specific KRT genes in Het-1A and EPC2 cell lines after
exposing the cells for 30 min per day to desired BM (100 µM) at pH 5.0 for one, three and six consecutive
days. In the majority of cases, investigated KRT genes revealed the most efficient changes in mRNA
expression reflecting these observed in human biopsies only when treatment was repeated for six
consecutive days in contrast to those recorded at one or three days. Thus, we conclude that six days
of treatment seems to be the most optimal for both tested cell-lines to induce a specific BE molecular
pattern and these conditions have been chosen for further analysis of a broader spectrum of genes.
Interestingly, for EPC2 cells three days of treatments were sufficient to induce this molecular pattern.
Thus, to determine whether and how low pH and/or BM exposure can affect mRNA expression of
squamous and columnar epithelium-specific genes observed in humans (Table 2), both Het-1A and
EPC2 cells were exposed for 30 min daily for six consecutive days with BM (50 µM and 100 µM) at
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pH 5.0, or with BM (50 µM and 100 µM) and medium adjusted to pH 5.0 applied separately. We found
that in EPC2 and Het-1A cells, BM at the concentration 50 µM at pH 5.0, as well as BM and acidified
medium (pH 5.0) applied separately were less effective in induction of gene expression changes
characteristic for BE patients in comparison to the experiments in which BM in higher concentration of
100 µM has been applied at pH 5.0. This clearly indicates that changes in the specific gene expression
are dependent on bile concentration and acidic environment. Moreover, we observed that incubation of
EPC2 cells with 100 µM of BM at pH 5.0 downregulated mRNA expression of all investigated squamous
epithelium-specific KRT genes as compared to untreated control cells. Interestingly, in Het-1A cells only
KRT15 mRNA expression was significantly downregulated. This is in accordance with observations
by Mari et al. [38], who claimed that Het-1A cells lacked the expression of majority of squamous
epithelium-specific KRT genes, confirming that this cell line has an incomplete squamous phenotype.
In addition, in our study, more columnar epithelium-specific genes were upregulated in Het-1A in
comparison to EPC2 under optimized experimental conditions. For instance, when Het-1A cells were
treated with 100 µM BM at pH 5.0, the expression of columnar epithelium-specific KRT8, TFF3, VIL1,
MUC2 and MUC13 was upregulated in comparison to untreated control cells. The same experimental
conditions in EPC2 cells provoked upregulation of columnar epithelium-specific KRT7, KRT18 and
TFF3 mRNA as compared to untreated control cells.
Summarized alterations in BE-specific gene expression observed in human biopsies and in vitro
and in vivo models were presented in Table 5.
Table 5. Summary of alterations in expression of squamous and columnar epithelium-specific genes
observed in human biopsies and in vitro using Het-1A and EPC2 cells and in vivo EGDA rat model.
A vertical up arrow (↑) indicates upregulation of mRNA expression in Barrett’s metaplasia as compared
with samples without Barrett’s metaplasia/untreated control cells/intact rats (background in orange);
a vertical down arrow (↓) indicates downregulation of mRNA expression in Barrett’s metaplasia as
compared with samples without Barrett’s metaplasia/untreated control cells/intact rats (background in
blue); a horizontal left right arrow (↔) indicates no changes in mRNA expression (background in dark
grey); n.a. indicates no amplification; n.d. not determined (background in light grey).
Gene Symbol Type of Epithelium
In Vitro Models
In Vivo Model Human Biopsies
Het-1A EPC2
KRT1 squamous n.a. ↓ ↑ ↓
KRT4 squamous n.a. ↓ ↓ ↓
KRT5 squamous n.a. ↓ ↑ ↓
KRT6 squamous ↔ ↓ n.d. ↓
KRT13 squamous n.a. ↓ ↓ ↓
KRT14 squamous n.a. ↓ ↑ ↓
KRT15 squamous ↓ ↓ ↓ ↓
KRT16 squamous ↔ ↓ n.a. ↓
KRT23 squamous n.a. ↓ ↔ ↓
KRT24 squamous n.a ↓ n.a. ↓
KRT7 columnar ↔ ↑ ↑ ↑
KRT8 columnar ↑ ↔ ↑ ↑
KRT18 columnar ↔ ↑ ↑ ↑
KRT20 columnar n.a. n.a. ↑ ↑
TFF1 columnar n.a. n.a. ↓ ↑
TFF2 columnar n.a. n.a. n.a. ↑
TFF3 columnar ↑ ↑ ↑ ↑
VIL1 columnar ↑ n.a. ↔ ↑
MUC2 columnar ↑ n.a. ↑ ↑
MUC3 columnar n.a. n.a. n.a. ↑
MUC5B columnar n.a. n.a. n.a.
MUC6 columnar n.a. n.a. n.a. ↑
MUC13 columnar ↑ ↔ ↑ ↑
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Based on our data, EPC2 and Het-1A cells react differently to the implemented chronic mixed acid
and bile treatment. Interestingly, when we took a deeper look into the outcome of our investigations
in vitro, we found that the expression pattern of analyzed genes demonstrated around 57% of similarities
between the human biopsies and the EPC2 cells treated with acidic BM (Figure 11, Table 5). In turn,
in Het-1A model only 26% of genes reflected the expression pattern similar to that obtained in biopsies
from BE patients (Figure 11, Table 5).
Figure 11. Venn diagram displaying numbers of up/downregulated genes in human biopsies derived
from patients with Barrett’s metaplasia as compared with in vitro Het-1A and EPC2 model of Barrett’s
esophagus. Overlap area shows the number of the same up/downregulated genes in the appropriate
groups. Graphs were obtained through Venn diagrams software (available online: http://bioinformatics.
psb.ugent.be/webtools/Venn/). Different colors mean different datasets.
Additionally, we have found that in animal BE model 45% of assessed genes were expressed in a
pattern characteristic for human BE metaplasia (Figure 12, Table 5). In turn, when expression profile of
both cell lines within the optimized in vitro BE model were analyzed together, 73% of genes reflected
alterations observed in human biopsies (Figure 12, Table 5).
Taken together, we conclude that our optimized in vitro model based on two primary immortalized
human esophageal squamous cell lines is suitable to observe an efficient induction marker specific
for human BE epithelium. However, it is worth mentioning that cell cultures apparently lack
systemic inflammatory response, the influence of esophageal microcirculation, microenvironmental
factors, neural components, neuropeptides and cellular interactions characteristic for esophageal cells
functioning in vivo [32,39]. Therefore, these doubts could be, at least in part, solved by studies in animal
models of BE in vivo providing additional information about macroscopic, microscopic, functional
and biochemical alterations. The animal model, applied simultaneously with the optimized in vitro
model, could offer the opportunity for the evaluation of the molecular response and the effectiveness
of possible drugs candidates targeting BE prevention and/or treatment.
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Figure 12. Venn diagram displaying numbers of up/downregulated genes in human biopsies derived
from patients with Barrett’s metaplasia as compared with in vitro (Het-1A and EPC2) models
and surgical animal model of Barrett’s esophagus. Overlap area shows the number of the same
up/downregulated genes in the appropriate groups. Graphs were obtained through Venn diagrams
software (available online: http://bioinformatics.psb.ugent.be/webtools/Venn/). Different colors mean
different datasets.
4. Material and Methods
4.1. Analysis of BE Expression Profile for Selected Genes in Human Biopsies Based on GSE Datasets
Expression profiles from human biopsies derived from patients with normal esophageal epithelium
and with diagnosed BE epithelium were obtained from Gene Expression Omnibus datasets GSE13083
(7 patients with normal vs. 7 patients with BE) [8], GSE34619 (8 patients with normal vs. 10 patients
with BE) [9] and GSE1420 (8 patients with normal vs. 8 patients with BE) [24]. The results demonstrated
on Table 1 are shown based on the analysis of the part of the data derived from the previously published
databases [8,9,24]. Analyses were performed in silico using the NCBI Gene Expression Omnibus (GEO)
database and the Gene Expression Omnibus 2R (GEO2R) tool (www.ncbi.nlm.nih.gov/geo/geo2r/).
The results were represented as a log2-fold change (logFC) in BE samples vs. normal esophageal
epithelium. For each logFC, an empirical Bayes moderated t-statistic was calculated by the software.
Adjusted p-values, corrected for multiple testing using the Benjamini and Hochberg false discovery
rate method, were taken for results interpretation. p < 0.05 was interpreted as statistically significant
and marked in the table with an asterisk (*) for the genes with logFC values higher than 2 or lower than
−2, which was considered as biologically significant up- or downregulation, respectively. Additionally,
we further analyzed genes that were included in all three GSE datasets and were significantly
up-/downregulated in at least one database.
4.2. Cell Cultures
The human SV40-immortalized esophageal squamous (Het-1A) epithelial cell line was a gift from
J. W. P. M. van Baal (Utrecht University, Utrecht, The Netherlands). Het-1A cells were cultured in
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serum-free EPM2 medium (AthenaES, Baltimore, MD, USA). Het-1A cells were grown on FNC Coating
Mix® (AthenaES, Baltimore, MD, USA) containing fibronectin, collagen and albumin. The primary
human telomerase reverse transcriptase (hTERT) immortalized esophageal epithelial (EPC2) cell line
was a gift from K. K. Krishnadath (University of Amsterdam, Amsterdam, The Netherlands). EPC2
cells were cultured in keratinocyte-SFM (Life Technologies, Paisley, UK) medium supplemented
with 50 µg/mL bovine pituitary extract (BPE) (Life Technologies, Paisley, UK) and 1.0 ng/mL human
recombinant epidermal growth factor (EGF) (Life Technologies, Paisley, UK). Both culture media were
supplemented with 100 U/mL penicillin and 50 mg/mL streptomycin (Sigma-Aldrich, Saint Louis, MO,
USA). Cells were maintained at 37 ◦C and 5% CO2 and detached from the flasks prior to subculturing
by the removal of the medium and the addition of 0.25% trypsin (Sigma-Aldrich, Saint Louis, MO, USA)
for 1 to 5 min. These cell lines were selected as the most appropriate to be tested in the experimental
model of BE, as described previously [1,32,38].
4.3. Acid/Bile Mixture (BM) Treatment
Het-1A and EPC2 epithelial cell lines were used to reflect the response of normal human esophageal
epithelium to low pH and/or BM exposure. Both cell lines were seeded at a density of 105 cells/well in
6-well plates. The cells were cultured until they reached approximately 40–50% confluence. At this
stage, the cells were subjected to 1, 3 and 6 days of acid and/or BM treatment, with a 30-min period of
exposure per day. The BM contained 25% deoxycholic acid, 45% sodium glycocholate hydrate and
30% sodium taurochenodeoxycholate (Sigma-Aldrich, Saint Louis, MO, USA); total BM concentration
used in final experiments was 50 and 100 µM. The acidified medium consisted of appropriate culture
medium adjusted to pH 5.0 in which pH was adjusted with 5 M HCl. Cells were also cultured in
regular medium (pH 7.3 for EPM2 medium; pH 7.2 for keratinocyte-SFM medium) with/or without
co-incubation with BM. After acid/BM exposure, the cells were rinsed with PBS, and then regular
medium was added. After the last day of exposure, cells were left for 24 h and then lysed for RNA
extraction. Cells were approximately 90% confluent at this time. The type and the molar ratio of bile
salts in the BM have been based on studies analyzing gastroesophageal refluxate of patients with
erosive esophagitis and BE [40,41]. Daily exposure time to BM and BM concentrations were selected
based on cell viability assay data, cell morphology observations and previously published data [40].
4.4. Cell-Viability Assays
Cell viability was evaluated using thiazolyl blue tetrazolium bromide (MTT) colorimetric assay
(Sigma-Aldrich, St. Louis, MO, USA). Het-1A and EPC2 cells were plated in 5 replicates in 96-well
plates at a density of 104 cells/well in a final volume of 100 µL medium. After overnight incubation at
37 ◦C, 5% CO2, dilutions of BM in acidified (pH 5.0) or regular medium were added in 5 replicates for
30 min. Untreated cells (appropriate volumes of medium added) served as controls. After 24 h, 50 µL
of the MTT solution was added to each well and incubated for 4 h at 37 ◦C. Medium was removed and
the formazan product of MTT reduction was dissolved in 75 µL of DMSO per well. The optical density
was measured at 550 nm.
4.5. Analysis of mRNA Expression by Real-Time Polymerase Chain Reaction (PCR)
Total RNA was isolated using commercially available kit with spin-columns (Universal
RNA/miRNA Purification Kit, EURx, Gdansk, Poland), according to the manufacturer’s protocol. RNA
concentration was measured using Qubit 4 fluorometer (Thermo Fisher Scientific, Waltham, MA, USA).
Reversed transcription to cDNA was performed using the High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Foster City, CA, USA), using 1,8 µg of RNA for each reaction well.
Relative gene expression was determined by real-time PCR according to the MIQE guidelines.
All reactions were performed in 96-well reaction plates in duplicates or triplicates via the Quant Studio
3 system (Applied Biosystems, Foster City, CA, USA). The 2× TaqMan Fast Advanced Master Mix
(Thermo Fisher Scientific, Waltham, MA, USA) and 20× TaqMan gene expression assays (Thermo Fisher
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Scientific, Waltham, MA, USA) were used according to the manufacturer’s protocol (see gene IDs in
Supplementary Materials Tables S1 and S2). PCR reaction conditions were as follows: (i) an initial
incubation at 50 ◦C for 2 min, (ii) denaturation at 95 ◦C for 2 min, (iii) 40 cycles of 95 ◦C for 1 sec and
60 ◦C for 20 s. The relative quantitation of gene expression was performed using the 2−∆∆CT method
with cDNA derived from untreated cells or physiological esophageal epithelium of rat as reference
samples. p < 0.05 was interpreted as statistically significant for at least a two-fold up/downregulation
in relative expression, which was considered as biologically relevant. Barrett’s-like samples were
selected in the number of 5 for gene expression analysis in animal biopsies.
4.6. Animal Model of BE
The study was approved by the I Local Animal Care and Use Ethical Committee held by
Jagiellonian University Medical College in Cracow and was run in compliance with the European
Union regulations, ARRIVE guidelines and with implications for replacement, refinement or reduction
(the 3Rs) principles, regarding handling of experimental animals (approval no 89/2017, permission
date: 22 November 2017 and approval no 23/2016, permission date: 20 July 2016).
Male Wistar rats (Rattus norvegicus) in the total number of 15 were used in the experiments. Animals
were fasted for 24 h before surgery with free access to drinking water. An anastomosis between the GEJ
and the duodenum (esophagogastroduodenal anastomosis, EGDA) on its anterior mesenteric border
was created to induce mixed duodenogastroesophageal reflux according to the method introduced by
Nishijima et al. [30] and based on the generation of a shortcut for the chronic mixed gastroduodenal
contents reflux through the damaged lower esophageal sphincter [15]. This surgical model with slight
modifications has been widely described in scientific literature [33,42]. Briefly, under general isoflurane
(2–4%) anesthesia, a midline laparotomy was performed and followed by a longitudinal incision
extending approximately 5 mm along the lower part of the anterior esophagus wall, including the GEJ
area. Next, the second incision of 5 mm in length was generated 4 cm distally from the Treitz ligament
on the anterior mesenteric border of the duodenum. These incisions were side to side anastomosed
using 7–0 silk sutures. The abdomen muscles and skin were closed separately with 4–0 silk sutures.
After the surgical procedure and during the recovery phase, rats were infused s.c. with 5–10 mL of
isotonic sodium chloride. For the next 10 weeks, the animals were fed a standard diet with free access
to the drinking water. After that period, animals were sacrificed by i.p. administration of a lethal dose
of pentobarbital (Biowet, Pulawy, Poland).
The esophagus and stomach were removed and opened longitudinally for macroscopic
examination. For microscopic evaluation biopsies containing the esophagus, the GEJ and forestomach
were sectioned. These segments were embedded in paraffin, cut into 4 µm sections and stained by
haematoxylin/eosin (H&E) and alcian blue/periodic acid-Schiff (AB/PAS) for microscopic evaluation.
Samples were evaluated using a light microscope (AxioVert A1, Carl Zeiss, Oberkochen, Germany).
Digital documentation of histological slides was obtained using the abovementioned microscope
equipped with automatic scanning table and ZEN Pro 2.3 software (Carl Zeiss, Oberkochen, Germany)
to collect multiple photographs of each histological sample and to stitch them into one picture; to obtain
better quality of each picture, the background was subtracted and unified as white [43]. Esophageal
mucosal samples were collected for biochemical and molecular assessments on ice, snap-frozen in
liquid nitrogen and stored at −80 ◦C until further analysis [43]. Blood samples were collected from the
vena cava and serum was stored at −80 ◦C until further analysis [43].
The macroscopic degree of the esophageal mucosa injury and disease progression was assessed
based on following criteria (lesion score):
0—physiological normal esophageal mucosa with squamous epithelium,
1—inflammation without ulcers reaching up to 1.5 cm of the esophagus as measured from GEJ,
2—inflammation without ulcers reaching beyond 1.5 cm of the esophagus as measured from GEJ,
3—inflammation with macroscopic ulceration and papillomatosis of the esophageal mucosa surface
reaching up to 1.5 cm of the esophagus as measured from GEJ,
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4—inflammation with macroscopic ulceration and papillomatosis of the esophageal mucosa surface
reaching beyond 1.5 cm of the esophagus as measured from GEJ.
Presence or absence of the following criteria was included in the microscopic and histological
analysis of the disease progression within esophageal mucosa:
1. hyperplasia of squamous epithelium,
2. fibrosis of lamina propria,
3. esophagitis: 1—thickening of squamous epithelium with basal cell layer occupying up to
30% of its height; elongation of connective tissue papillae, 2—regeneration layer occupying
50% of the epithelium thickness; hyperemia and scanty inflammatory infiltrate are present
in connective tissue papillae, 3—expansion of the regeneration zone to 75% of the epithelial
height; moderate inflammatory infiltrate in connective tissue papillae, 4—ulceration or massive
inflammatory infiltrate,
4. Barrett’s-like lesion with the presence of goblet cells.
4.7. Determination of Serum Content of Pro- and Anti-Inflammatory Factors by Luminex Microbeads
Fluorescent Assays
Serum concentration of IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, TNF-α, IFN-γ, GM-CSF was
assessed using the Luminex microbeads fluorescent assays (Bio-Rad, Hercules, CA, USA) and Luminex
MAGPIX System (Luminex Corp., Austin, TX, USA). Results were calculated from the calibration
curves and expressed in pg/mL, according to the manufacturer’s protocol, as described previously [43].
4.8. Statistical Analysis
Analyses were performed using GraphPad Prism 5 (GraphPad Prism Software Inc., San Diego,
CA, USA). Results are presented as mean ± SEM. Statistical analysis was performed with Student’s
t-test or ANOVA with Dunnett’s multiple comparison if more than two experimental groups were
compared. For all statistical analyses, the level of significance was set as p < 0.05.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/17/6436/s1,
Table S1: The list of selected human genes (and reference genes) and the corresponding TaqMan assays; Table S2:
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